

Almudena González-Domínguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4075671/publications.pdf>

Version: 2024-02-01

13
papers

116
citations

1307366

7
h-index

1372474

10
g-index

13
all docs

13
docs citations

13
times ranked

127
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 329.	1.0	30
2	The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. <i>European Journal of Health Economics</i> , 2019, 20, 135-147.	1.4	15
3	Economic valuation of informal care in cerebrovascular accident survivors in Spain. <i>BMC Health Services Research</i> , 2013, 13, 508.	0.9	13
4	Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. <i>BMC Health Services Research</i> , 2014, 14, 46.	0.9	10
5	The social return on investment of a new approach to heart failure in the Spanish National Health System. <i>ESC Heart Failure</i> , 2020, 7, 131-138.	1.4	10
6	Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1076-1084.	1.2	9
7	Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. <i>Journal of Medical Economics</i> , 2020, 23, 1418-1424.	1.0	9
8	Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study. <i>Global & Regional Health Technology Assessment</i> , 2020, 7, 50-56.	0.2	7
9	Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. <i>Gynecologic Oncology</i> , 2022, 164, 406-414.	0.6	4
10	Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 8-13.	0.2	3
11	Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain. <i>Advances in Therapy</i> , 2021, 38, 4057-4069.	1.3	3
12	Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain. <i>Vaccine</i> , 2021, , .	1.7	2
13	Costs of the management of hemophilia A with inhibitors in Spain. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 35-42.	0.2	1